Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

Francesco Pantano, Francesco Maria Guida, Caterina Vivaldi, Bruno Vincenzi, Enrique Grande, Mercedes Rodriguez Garrote, Michele Caraglia, Nicola Silvestris, Enrico Vasile, Gianluca Masi, Alfredo Falcone, Giuseppe Tonini, Daniele Santini

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)467-468
Number of pages2
JournalCancer Biology and Therapy
Volume14
Issue number6
DOIs
Publication statusPublished - 2013

Keywords

  • Anti-EFGR
  • Body mass index
  • Cancer
  • Cetuximab
  • Colorectal cancer
  • FBG
  • TTP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Pantano, F., Guida, F. M., Vivaldi, C., Vincenzi, B., Grande, E., Garrote, M. R., Caraglia, M., Silvestris, N., Vasile, E., Masi, G., Falcone, A., Tonini, G., & Santini, D. (2013). Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 14(6), 467-468. https://doi.org/10.4161/cbt.24346